Father Of Sports Medicine Beat His Own Physical Challenges

 Dr. Robert Kerlan refused to give in to his body's limitations. And in doing so, he pioneered sports medicine and showed pro athletes how to overcome limits too.

Kerlan (1922-1996) faced his first barrier in his early 20s. He was diagnosed with ankylosing spondylitis, a painful inflammatory disease of the spine and large joints. Still, he chose to become an orthopedic surgeon.

Performing surgery eventually became impossible due to Kerlan's disease. His hands became arthritic and he couldn't stand up long enough. Kerlan became progressively severely hunched over and was eventually permanently on crutches. He wound up undergoing four hip replacements because of his condition.

But Kerlan focused on what he could still do: apply his ideas to the field. He became renowned for the treatment and diagnostic methods he developed.

Kerlan's determination led to him not just living with his disability but overcoming it to help others.

Kerlan: Find Your Way Through Difficulty

In 1965 Kerlan co-founded the famed Kerlan-Jobe Orthopedic Clinic in Los Angeles with Dr. Frank Jobe. Kerlan was well-known as the long-time physician of the three main Los Angeles professional sports teams: the Dodgers, Lakers and Rams, where his title was medical director.

Dr. Ralph Gambardella, an orthopedic surgeon at the Kerlan-Jobe Institute, worked with Kerlan from 1982 until Kerlan's 1996 death.

"There was no sports medicine and Kerlan recognized that taking care of athletes required a different approach," Gambardella told IBD. "Athletes have special-needs problems, expectations, recovery and return-to-play time frames to deal with. All of that required the continuous development and evolution of new and innovative techniques and treatments."

"No one else was doing that at that time, which is why we refer to Dr. Kerlan as the Godfather of Sports Medicine," Gambardella said.

Some of the legendary Hall of Fame athletes who put their trust in Kerlan were basketball players Elgin Baylor, Jerry West, Wilt Chamberlain and Kareem Abdul-Jabbar. Dodgers pitcher Sandy Koufax was a Kerlan patient as were Rams football star Merlin Olsen and jockey Bill Shoemaker.

Kerlan and Jobe were also team physicians for the Los Angeles Angels of Anaheim, the Los Angeles Kings and a host of professional and college teams throughout the region.

Kerlan's legacy was so significant that on the day he died, flags at Dodger Stadium flew at half-staff and players and fans observed a moment of silence for Kerlan.

In 1996 Kerlan was inducted into the Southern California Jewish Sports Hall of Fame.

Use Humor As Treatment Like Kerlan

Seeing the light side of life helped Kerlan cope. "In addition to being a brilliant orthopedic surgeon, Dr. Kerlan had a sense of humor, loved all sports and was humble," said Hall of Fame basketball player Jamaal Wilkes, a former Laker. "Dr. Kerlan used his sense of humor to put his patients at ease."

Humor was vital to Kerlan's outlook on his career and life. He told the Los Angeles Times in 1992 the only time he really thought about his condition was when he went into a stadium on the road.

"Here I am walking on crutches, and it seems like I'm barely able to get around, and someone asks, 'Who are you?' I say 'I'm a doctor who takes care of the Rams or whatever team I'm with.' Oftentimes I get a double-take," he said.

"It's the same feeling I get when I walk into a room at the clinic and a (new) patient says, 'My God, what happened to you?' " Kerlan said. "When somebody makes you stop and look at it, it is kind of funny."

Forge Your Path

Kerlan was born in Bowlus, Minn. The future doctor was the son of a country doctor.

The man who would go on to treat famous athletes was an accomplished sportsman himself. When Kerlan graduated from Aitkin High in rural Minnesota at 16 he'd earned nine letters in sports.

The 6'2" Kerlan then attended University of California, Los Angeles, beginning in 1939. He was on the basketball team and lettered. Kerlan eventually left UCLA for the University of Southern California where he completed his undergraduate work and then his medical studies.

During World War II in 1944, Kerlan discovered in a medical exam for the armed forces he had ankylosing spondylitis in his spine, shoulders and hips. He was rejected for service.

He resumed his studies and graduated from USC Medical School in 1945. Kerlan began his private practice in 1950. And Kerlan began his sports medicine career as a volunteer for a minor league baseball team in Los Angeles.

Take The Initiative

When Major League Baseball came to Los Angeles in 1958 as the Dodgers relocated from Brooklyn, Kerlan decided he, too, was ready for the big leagues.

Kerlan boldly reached out to Dodgers' General Manager Buzzie Bavasi. And Kerlan suggested he become the team's physician.

Team physicians weren't a priority in sports teams back then. In fact Kerlan didn't receive an interview until the day before the season opened. He got the job but Bavasi wasn't sold on the importance of the position.

By the Dodgers' second season in Los Angeles, they'd won the World Series and Bavasi had changed his mind. He saw how Kerlan helped keep the team's aging stars productive.

"In 1959, when we won the pennant, Dr. Kerlan was our Most Valuable Player," Bavasi told the Los Angeles Times. "Kerlan made us realize there was such a thing as sports medicine. He was very popular. The players knew that because he was in pain, he understood their pain."

Kerlan: Apply Hands-On Experience

Kerlan didn't allow his condition to stop his work. And his work ethic revolutionized the idea of sports medicine.

"I'd get up early and cover patients in hospitals, operate two or three mornings a week and go to the office and see patients until 6 p.m.," Kerlan said." "Then I'd go to one stadium or another."

Kerlan was the sole doctor covering some 240 home games of local teams for several years, the Los Angeles Times said.

Know Knowledge Wins Out

One of Kerlan's initially skeptical new patients back in the early 1960s was future basketball Hall of Famer and legend Elgin Baylor of the Lakers.

Baylor suffered from consistent pain in his knees when doctors recommended he see Kerlan.

In Kerlan's office waiting for his first appointment, Baylor caught a glimpse of the doctor. "An extremely hunched-over man ... walking with two crutches," Baylor wrote in "Hang Time: My Life in Basketball."

"(Dr. Kerlan) looks like a question mark. ... He acknowledges me by lifting a crutch and aiming its rubber tip at me. This guy can barely help himself. How the hell can he help me?" Baylor wrote.

Baylor immediately left. When he couldn't find a doctor to help his ailing knees, Baylor gave Kerlan a chance. "We should be trying to banish prejudice of all kinds," Baylor realized. "I should not be biased against Dr. Kerlan because of his physical condition."

After an extensive examination and battery of tests, Kerlan's thoroughness won. He told Baylor he didn't have calcium deposits in his knees as other doctors said. Kerlan said Baylor had them in is quadriceps. That meant Baylor didn't need surgery as he'd been told, but a special therapy Kerlan developed.

"Not only (did) I find Kerlan to be one of the smartest men I've ever met, but we became lifelong friends," Baylor wrote.

When Baylor, at 30, suffered a catastrophic knee injury in the 1965 playoffs, Kerlan repaired the knee. He cautioned Baylor he'd never be the same player. But the combination of Kerlan's still-surgical skill and Baylor's determination led to him still being good enough to make four All-Star teams in the next five years.

Teach Your Mantra

Kerlan's daughter Kimberly Higgins told the Los Angeles Times that she inherited the same disease that her father had. When she was in college she had a flare-up of severe pain. She limped into the kitchen and told Kerlan she was in too much pain to go to school.

She recalled her father saying " 'Oh, yes, you will. You can never, ever give in to this. You have to be in charge.' He added, 'You have to be stronger than this disease.' "

Robert Kerlan's Keys

• Considered the pioneer of sports medicine as co-founder of the Kerlan-Jobe Institute orthopedic clinic.
• Overcame: Ankylosing spondylitis diagnosis in his early 20s, a painful inflammatory disease of the spine and large joints.
• Lesson: "You can never, ever give in to this. You have to be in charge. You have to be stronger than this disease."
• https://www.investors.com/news/management/leaders-and-success/robert-kerlan-overcame-physical-challenges-to-help-others/

Lifelong Democrat Lawmaker To Vote Republican In NY Governor Race: 'Hochul Has No Clue'

 by Bill Pan via The Epoch Times (emphasis ours),

Frustrated with New York Gov. Kathy Hochul’s halfhearted attempt to get serious on crime, a decades-long Democrat state lawmaker says he will vote for her Republican challenger in the upcoming election.

“The No.1, No.2 and No.3 issues for New Yorkers are crime, crime, crime,” Dov Hikind, a Brooklyn Democrat who had served as an assemblyman in the New York State Legislature for 35 years until 2018, told The Epoch Times’ sister media NTD News after the last and only debate before the Nov. 8 gubernatorial race.

During the hour-long debate on Tuesday night, Hochul faced off with Rep Lee Zeldin (R-N.Y.) and took on topics including the economy, abortion, and COVID vaccine mandates. But the most heated exchange took place when Zeldin charged Hochul with failing to address rampant subway crimes and hate crimes targeting Jewish and Asian communities.

Hochul, who ascended to the governorship after former Governor Andrew Cuomo resigned amid a sexual harassment scandal, fired back by accusing the Long Island Republican of trying to “keep people scared” about crimes more than they should, while insisting that her criminal justice policies are “making a difference.”

“Anyone who commits a crime under our laws, especially with the change they made to bail, has consequences. I don’t know why that’s so important to you,” the Democrat incumbent said at one point.

Hochul’s response, Hikind said, shows that she “has no clue” whatsoever as to what concerns New Yorkers the most.

“There’s a 40 percent decrease in the number of people using the New York City subway system. That’s crazy,” he told NTD News. “I don’t blame people. They’re afraid. They’re concerned. They see the things that are happening on the subway system and in the streets of New York.”

“Hochul has no clue, and I think it was very clear last night,” Hikind continued, adding that he was “dumbfounded” about whether Hochul has a plan for the future at all. He also pointed to the fact that the governor didn’t start campaigning on the issue of crime until very recently when polls showed Zeldin steadily narrowing her lead.

In a campaign ad launched last week, Hochul highlighted her opponent’s ties to President Donald Trump. The ad features footage of Trump at an April 2022 event at his Mar-a-Lago home saying, “Lee fought for me very, very hard.” It also shows Trump giving Zeldin a supportive tap on the shoulder.

“Zeldin voted with Trump, too—nearly 90 percent of the time, against tougher gun laws, for extreme anti-abortion laws,” the narrator says in an ominous voice. “Zeldin even voted to overturn the 2020 election to keep Trump in power.”

https://www.zerohedge.com/political/lifelong-democrat-lawmaker-vote-republican-ny-governor-race-hochul-has-no-clue

New cancer fighting compound

 A University of Kentucky Markey Cancer Center researcher's team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors.

The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah's lab as the paper's first author.

The new gold-derived compounds created by Awuah's lab were toxic to cancer cells but well-tolerated by mice, giving them potential in the development of new cancer drugs that could make it to the clinic.

Many metal-based therapies have proven to be effective against cancer, with platinum-based drugs a first line chemotherapy for testicular, bladder, lung, colon and ovarian cancers. Some metal-based compounds, like gold(III), have promise as anticancer agents, but lack the stability needed to continue therapeutic development.

Awuah's lab synthesized a new class of gold(III), which had a different structure that was more tolerant to therapeutic use.

In the lab, the new chiral gold(III) compounds were studied on a panel of cancer cell lines to test their effectiveness and understand how they attack cancer cells.

The compounds showed anticancer activity against aggressive triple negative breast cancer cells. They also possessed a new mechanism that caused the cells' mitochondria to dysfunction.

Awuah says developing drugs that cause mitochondria dysfunction deprive cancer cells of energy and is a new relevant strategy to inhibit cancer growth that would be useful in combination with existing therapies.

"Continuing to develop gold-based compounds has the potential to generate new mechanisms of drug action and understanding how they alter cancer cells has significant implications in drug design and is of clinical relevance," Awuah said.

Awuah is an assistant professor in the College of Arts and Sciences' Department of Chemistry and holds a joint appointment in the College of Pharmacy's Department of Pharmaceutical Sciences. His lab focuses on developing new methods to create chemical tools that interrogate complex biological processes as therapeutics for several diseases, including cancer.

---

Story Source:

Materials provided by University of Kentucky. Original written by Elizabeth Chapin. Note: Content may be edited for style and length.

---

Journal Reference:

1. Adedamola S. Arojojoye, Jong H. Kim, Chibuzor Olelewe, Sean Parkin, Samuel G. Awuah. Chiral gold(iii) complexes: speciation, in vitro, and in vivo anticancer profile. Chemical Communications, 2022; 58 (73): 10237 DOI: 10.1039/D2CC03081K

https://www.sciencedaily.com/releases/2022/10/221027154154.htm

Why shingles can lead to stroke

 Scientists investigating why people who have had shingles are at a higher risk of stroke, now believe the answer lies within lipid vesicles called exosomes that shuttle proteins and genetic information between cells, according to new research from the University of Colorado Anschutz Medical Campus,

The study, published today in The Journal of Infectious Diseases, details the mechanisms behind the link between shingles and strokes.

"Most people know about the painful rash associated with shingles, but they may not know that the risk of stroke is elevated for a year after infection," said the study's lead author Andrew Bubak, PhD, assistant research professor in the Department of Neurology at the University of Colorado School of Medicine. "Importantly, the rash is often completely healed and individuals feel normal but nonetheless are walking around with this significant elevation in stroke risk."

Herpes zoster (HZ) or shingles is caused by the varicella zoster virus which causes chicken pox. The virus lingers in the ganglionic neurons and can reactivate causing excruciating pain. But researchers have found that shingles can also increase the risk of stroke especially for those under age 40 where the shingles vaccine is not typically recommended.

The risk is greatest in people with the rashes on their faces, perhaps due to the proximity to the brain.

To better understand how this works, Bubak and his team began looking more closely at exosomes.

"Exosomes carry pathogenic cargo that can cause thrombosis and inflammation distant from site of actual infection," Bubak said. "That could ultimately lead to a stroke in patients."

Researchers collected plasma samples from 13 patients with shingles and 10 without. The samples were taken at time of infection and at 3-month follow-ups for a subset of patients and exosomes were extracted from the plasma.

The researchers found prothrombotic exosomes which could cause blood clots in those with the infection. They also discovered proinflammatory exosomes that also pose risks for stroke at the 3-month follow-up.

Bubak said the findings suggest that in a subset of people with shingles, the virus may not return to latency or the circulating exosomes that induce a prolonged prothrombotic state may persist even after therapy is done and the rash is gone. He said using antiviral agents longer with the addition of antiplatelet and anti-inflammatory agents could help.

"As well as initiatives to increase HZ vaccine uptake to decrease stroke risk, particularly in individuals with known preexisting stroke risk factors," said Bubak. "If these findings are confirmed with a larger longitudinal study, then this could change clinical practice."

Most physicians are unaware of the connection between shingles -- which has an effective vaccine -- and stroke.

"But it's really important and so easily mitigated," Bubak said. "Send them home with antiplatelet agents."

Story Source:

Materials provided by University of Colorado Anschutz Medical Campus. Original written by David Kelly. Note: Content may be edited for style and length.

---

Journal Reference:

1. Andrew N Bubak, Christina Coughlan, Janelle Posey, Anthony J Saviola, Christy S Niemeyer, Serena W R Lewis, Sara Bustos Lopez, Adriana Solano, Stephen K Tyring, Cassidy Delaney, Keith B Neeves, Ravi Mahalingam, Kirk C Hansen, Maria A Nagel. Zoster-Associated Prothrombotic Plasma Exosomes and Increased Stroke Risk. The Journal of Infectious Diseases, 2022; DOI: 10.1093/infdis/jiac405

What Xi Jinping’s third term means for science

 China’s ambitions and reliance on science and technology were front and centre at the Communist Party’s all-important 20th congress in Beijing, which ended on Sunday.

President Xi Jinping said at the opening of the meeting, held every five years, that the country must “regard science and technology as our primary productive force, talent as our primary resource and innovation as our primary driver of growth”.

On Sunday, he was reinstated as general secretary of the party for a third term, breaking a convention established four decades ago, and there was a major reshuffle of the party’s senior leadership. The decision-making body called the Politburo gained several members with qualifications or experience working in science or technology: 6 out of 25 members now have a science background, compared to just one member in the previous Politburo.

Nature spoke to science-policy analysts about Xi’s opening address, a shortened version of a written report that sets the agenda for the party to 2027 and beyond.

Science funding

Analysts say that China’s epic investment in science is likely to continue.

In 2021, China spent 2.8 trillion yuan (US$386 billion) on research and development (R&D), accounting for 2.4% of its gross domestic product (GDP), a measure known as R&D intensity. The country’s most recent five-year plan aims for an increase of more than 7% every year from 2020 to 2025. If that continues until 2035, China’s R&D intensity could reach parity with the average for countries in the Organisation for Economic Co-operation and Development, which has reached close to 2.7%, says Marina Zhang, who studies innovation in China at the University of Technology Sydney in Australia. However, China’s below-target GDP growth this year could mean businesses will find it harder to increase their investment in R&D, she says.

There is little doubt that China will strengthen its R&D investment despite the economic situation, says Futao Huang, a researcher in higher education at Hiroshima University in Japan. The importance of science and technology is reflected in how often the term appears in the written congress report — 44 times, compared with 17 times in the 2017 report, 16 times in 2012 and 15 times in 2007, according an analysis by Jing Qian, who heads the Asia Society Policy Institute’s Center for China Analysis in New York City.

Qian’s analysis also found that some 42 officials with formal degrees and work experience in science have been selected for the Central Committee, a political body that comprises the party’s top leadership, including the Politburo. These members typically go on to head government bodies, including science-related ministries and research-funding agencies.

Semiconductors and self-reliance

Earlier this month, the United States introduced new restrictions on exports of advanced semiconductor technology, along with manufacturing equipment and know-how, to China. The controls are the latest in a long line of US-imposed barriers to the trade on which China would have relied to build its innovation economy. Xi’s speech stressed the importance of self-reliance in science and technology; researchers say this priority could translate to increased investment in strategically important industries such as semiconductor manufacturing, the digital economy, quantum computing and biomedicine. “If you can’t buy it, you’ve got to make it,” says Denis Simon, who studies Chinese science and innovation at Duke University in Durham, North Carolina.

But researchers will be watching how China plans to allocate funds. Zhang says more of the money will need to go to fundamental research, and companies will need to shoulder more of that investment, which so far has come mostly from the government.

The report’s nod to the business sector’s major role in allocating R&D investment is encouraging, says Zhang. “Innovation requires diversity, innovation requires autonomy and innovation needs to tolerate failures,” she says. But Qian says the central government has increasingly been intervening in market dynamics, and this is likely to continue. In such an environment, the bulk of the money will probably continue to flow to researchers at state-owned enterprises, leading technology firms and top universities, and less will go to those at smaller companies and universities. Qian says China’s scientific community does not seem very optimistic about the research environment, owing to policies that impinge on academic freedom.

China is also expected to prioritize research in aerospace — including space science — defence, climate change, clean energy and agriculture, among other areas, says Qian.

Talent drive

Xi’s speech noted that China already has “the largest cohort of research and development personnel in the world”. He said that to boost innovation, investments in the country’s skilled workforce will continue.

Studies have shown that despite huge efforts to train China’s researchers in some areas such as artificial intelligence, “there is still a quality gap”, says Jacob Feldgoise, who studies science and technology in China at the Center for Security and Emerging Technology at Georgetown University in Washington DC. For example, Chinese researchers produce more artificial-intelligence publications than do researchers in the United States, but US papers garner double the share of global citations.

To boost the workforce, China could try to recruit international researchers and entice back Chinese scholars based overseas, alongside training local scientists, say researchers. But hiring foreign talent is a sensitive topic, Simon says, so local efforts “will be given high priority and the overseas recruitment will be more quietly done, without fanfare”. In recent years, scientists in the United States have come under scrutiny for not declaring financial ties to talent-recruitment programmes in China.

Some analysts suggest that political tensions between the United States and China have spilled over into science. In the past few years, fewer researchers have been declaring dual US–China affiliations in their publications, and there has been a decline in the number of publications co-authored by scientists in the two countries. In the short to medium term, US and Chinese researchers will probably continue to engage, but at nowhere near the levels observed “during the heyday of bilateral cooperation”, in the 1990s through to the mid-2010s, says Simon. China’s increased emphasis on fostering home-grown talent could come with more pressure to show results, he adds. “It is no longer simply desirable for China to improve its innovation performance; it is now a national imperative.”

Even so, China intends to “expand science and technology exchanges and cooperation with other countries”, says the congress report. This could see China shifting away from working with the United States to focus on other regions, such as Europe, Australia or Canada, and even expanding its scientific ties with countries involved in its global infrastructure plan, the Belt and Road Initiative, says Simon.

Zero COVID

Researchers in China say travel restrictions under the country’s stringent zero-COVID policy have made it difficult for them to develop and maintain relationships with peers abroad. Limited availability of flights, high ticket costs and extensive quarantines mean that it is almost impossible to travel abroad or for foreign scientists to enter China, says Cong Cao, a science-policy researcher at the University of Nottingham Ningbo China, who is eager to meet face-to-face with overseas colleagues and attend international conferences again.

Before the congress, analysts presented conflicting views on whether restrictions could ease soon. Xi mentioned zero-COVID only once during his speech — to point out its merits. Qian says this might be because zero-COVID is an established policy, so Xi saw no need to elaborate on it. Or it could indicate that Xi wants to maintain flexibility and is open to change, says Qian.

Some researchers say it is possible that China will try lifting some restrictions after the party congress, but others say it won’t budge until the country’s legislative body, the National People’s Congress, meets early next year.

doi: https://doi.org/10.1038/d41586-022-03414-z

https://www.nature.com/articles/d41586-022-03414-z

Democrats Want You to Keep Paying More. This is How They're Making it Happen

 As inflation hits 40-year highs and Americans pay more for basic goods like food, shelter and transportation, Democrats don’t seem to care. They’re not just playing a fiddle as America burns, but they’re throwing proverbial fuel on the fire.

Whether it’s President Biden shutting down American energy independence, having James Taylor play a party as the stock market crashes or banning the sale of gas-powered cars while American’s can barely afford to put food on the table, Democrats don’t seem to care about how much things cost to average Americans.

In fact, some of our leaders seem upset about the prices that remain low.

Take for example White House Economic Advisor Tim Wu, who complained that low prices of flour are bad as that makes it harder for artisan bread makers to compete. Consider Sen. Elizabeth Warren, who said we need a “climate adjustment fee” — or, more taxes and higher prices at the pump. And of course, there is Federal Trade Commission Chair Lina Khan, who became famous for wanting to launch a case against Amazon because its prices are too low. None of them have a background in economics or have worked in the private sector, and at least two of them are millionaires.

These policymakers, like many in the Democratic Party, are out of touch with the average American. And they themselves don’t have to worry about affording their groceries, rent or gas.

In fact, the one thing they all have in common is professorship at Ivy League law schools — an industry that has no problem with ever-increasing prices, which neither Wu, Khan nor Warren have brought actions to investigate.

Now, we are seeing the desire to push prices higher make its way into lawsuits. Most recently, this was found in two cases against Amazon from the Democrat Attorneys General of California and Washington, DC. Both suits are ultimately centered around the complaint that Amazon requires third-party sellers to show the lowest prices possible for their goods on Amazon.com. In an effort to make sure that customers have access to low-priced goods, Amazon will not feature a product if it’s being sold lower elsewhere. Amazon is more interested in customers being able to afford the products they need, rather than making a one-off sale and risk losing that customer’s future business. But California and DC’s AGs don’t like this.

In the DC lawsuit, the AG said Amazon’s requirement that a person selling on Amazon.com cannot have a higher price on another site like Walmart.com was bad. Amazon did this to make sure its customers had the lowest prices, but DC’s AG said that because of this requirement, the seller was forced to raise its prices at other retailers. The suit failed miserably, and the DC Court threw it out.

It sounds like an interesting theory until you realize that Walmart.com would happily have the government help it get a lower price against its main competitor — Amazon. This then reveals the ridiculousness of this legal “theory”: that these sellers are so weak that they have to kowtow to Amazon’s pricing demands but so strong they can bully Walmart - the largest retailer on the planet.

In reality, the facts and logic show that Amazon’s policies resulted in lower prices for customers — which is why the judge threw out the DC case. Taken to its logical conclusion, DC’s AG basically argued that Amazon shouldn’t get the lowest prices possible for customers, meaning that the AGs pursuing this case and similar ones, whose job it is to protect citizens, want to raise prices. So much for consumer welfare.

This all circles back to the clear notion that many Democrats, whether they be in the Biden Administration like Khan and Wu, in Congress like Sen Warren or the DC and CA attorneys general, have no interest in lower prices for us. Perhaps, that is ultimately the point.

Carl Szabo is Vice President and General Counsel for NetChoice, and a professor of internet law at the George Mason Antonin Scalia Law School.

https://www.realclearpolicy.com/articles/2022/10/28/democrats_want_you_to_keep_paying_more_this_is_how_theyre_making_it_happen_861736.html

EU renews order for Illumina to keep Grail as separate entity

 EU antitrust regulators on Friday renewed interim measures ordering U.S. life sciences company Illumina to keep Grail as a separate entity pending an order to unwind the takeover completed before the deal had been approved.

The interim order, which was due to expire at the end of the month, was issued by the competition enforcer last year after Illumina jumped the gun and acquired Grail before securing the EU green light.

The EU subsequently vetoed the deal on Sept. 6.

"The European Commission has renewed and adjusted, under the EU Merger Regulation, the interim measures that ensure that Illumina and GRAIL remain separate following the Commission's decision to block the merger," the EU watchdog said in a statement.

Under the interim measures, Grail must be run by independent managers exclusively in the interest of the company and it cannot share confidential business information with Illumina, though there could be very limited exceptions with safeguards.

Illumina, which has challenged the Commission's veto, will be required to provide funds for Grail to develop cancer detection tests it has in the pipeline.

Failure to comply would trigger penalty payments up to 5% of Illumina's average daily turnover.

https://finance.yahoo.com/news/eu-renews-order-illumina-keep-124609346.html